Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Therapy01:25

Cognitive Therapy

571
Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
571
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

207
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
207
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

530
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
530
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

273
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
273
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

336
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
336
Depression: Overview01:18

Depression: Overview

505
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
505

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactory impairment in Huntington's disease: A systematic review and meta-analysis.

Neuroscience applied·2026
Same author

Application of the research domain criteria in early-phase clinical development of transdiagnostic neurotherapeutics: A multidisciplinary perspective.

Neuroscience applied·2026
Same author

Everyday stress-induced neurobehavioral dysregulation: therapeutic targets for management with Neurexan.

Frontiers in psychiatry·2025
Same author

EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Insights from an academic endeavor into central nervous system drug discovery.

Neural regeneration research·2024
Same author

Still in Search for an EAAT Activator: GT949 Does Not Activate EAAT2, nor EAAT3 in Impedance and Radioligand Uptake Assays.

ACS chemical neuroscience·2024

Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

935

Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.

Igor Magaraggia1, Zilla Kuiperes2, Rudy Schreiber1

  • 1Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology, Maastricht University, Maastricht, the Netherlands.

Neurobiology of Learning and Memory
|May 28, 2021
PubMed
Summary

Psychedelics may treat major depressive disorder (MDD) by enhancing cognitive flexibility and reducing negative bias. This approach targets core symptoms, potentially improving pattern separation and neurogenesis for better mental health outcomes.

Keywords:
Cognitive flexibilityHippocampal neurogenesisNegativity biasPattern separationResearch Domain Criteria

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.7K

Related Experiment Videos

Last Updated: Nov 4, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

935
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.7K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) presents significant heterogeneity, complicating treatment efficacy.
  • The Research Domain Criteria (RDoC) framework offers a dimensional approach focusing on neurobiology.
  • Psychedelics show promise for antidepressant activity, potentially through psychobiological mechanisms.

Purpose of the Study:

  • To propose a theoretical model explaining how psychedelics reduce negativity bias in MDD.
  • To investigate the role of pattern separation and neurogenesis in psychedelic antidepressant effects.
  • To establish a translational framework for developing novel MDD therapeutics targeting cognitive symptoms.

Main Methods:

  • Analysis of psychobiological, circuitry, and cellular/molecular mechanisms of psychedelic action.
  • Hypothesizing impaired pattern separation as a cause of negativity bias in MDD.
  • Examining the impact of psychedelics on hippocampal neurogenesis and prefrontal cortex synaptogenesis.

Main Results:

  • Psychedelics may enhance cognitive flexibility, normalize negativity bias, and reduce rumination.
  • The proposed model suggests psychedelics improve pattern separation, counteracting MDD's negative cognitive bias.
  • Psychedelics stimulate neurogenesis and synaptogenesis, promoting resilience and modulating key brain connectivity hubs.

Conclusions:

  • Psychedelics offer a potential therapeutic avenue for MDD by targeting cognitive symptoms.
  • Enhancing pattern separation and neurogenesis are key mechanisms for psychedelic antidepressant effects.
  • A new translational framework can guide the development of next-generation MDD therapeutics.